EpCAM-Binding Fn3 Polypeptides for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ligands for targeting epithelial cell adhesion molecule (EpCAM) in cancer treatment have low affinity, insufficient specificity, and production difficulties, limiting their effectiveness in cancer therapy and monitoring.
Innovation Solution
Development of polypeptides with specific amino acid sequences that have high sequence identity to certain SEQ ID numbers, capable of binding to EpCAM, and their use in conjugates with detectable or biologically active agents for targeted cancer therapy and diagnostics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ligands (antibodies, fragments, vNARs, DARPins, cyclic peptides) are used for EpCAM binding, then target coverage is achieved, but binding affinity is low and specificity is insufficient
Solution Approach 1:
The patent modifies amino acid sequences of fibronectin type III domains through systematic mutagenesis and selection to optimize binding parameters. Specific mutations in loops L1, L2, and L3 of the Fn3 domain have been shown to enhance EpCAM binding affinity while maintaining structural stability, directly addressing the low affinity issue of conventional ligands
Solution Approach 2:
The invention creates chimeric proteins by fusing EpCAM-binding Fn3 domains with other functional domains (such as Fc regions, toxin domains, or imaging moieties). This composite approach combines the high specificity of the Fn3-EpCAM interaction with additional functionalities, achieving both high affinity binding and enhanced therapeutic or diagnostic capability
2Reliability
If large molecular ligands (antibodies, antibody fragments) are used for EpCAM targeting, then target binding is achieved, but production and downstream handling become difficult
Solution Approach 1:
The patent extracts and isolates the minimal EpCAM-binding functional unit from complex antibody structures, utilizing only the fibronectin type III domain (approximately 10-15 kDa) which contains the essential binding interface. This extracted domain can be produced recombinantly in simple systems like E. coli, avoiding the complex production requirements of full antibodies while retaining target binding capability
Solution Approach 2:
The Fn3 domain ligands are designed as small, stable, and inexpensive to produce compared to antibodies. Their small size allows for simplified purification and formulation, and they can be produced at low cost using bacterial expression systems, making them economically viable for clinical applications
3Productivity
If conventional EpCAM ligands are used, then some binding activity is achieved, but affinity and therapeutic effectiveness are limited
Solution Approach 1:
The patent employs phage display and other in vitro selection methods to pre-select and optimize Fn3 domain variants with high EpCAM affinity before in vivo application. Through multiple rounds of selection and screening, ligands with optimized binding characteristics are identified and characterized, ensuring high therapeutic effectiveness from the outset
Solution Approach 2:
The invention utilizes the inherent flexibility of the Fn3 domain structure, particularly in the loop regions, to achieve high affinity binding. The dynamic conformational adaptability of these loops allows the domain to optimize its binding interface with EpCAM, achieving picomolar affinity that far exceeds conventional rigid antibody fragments
Data Source
AI summary
Certain embodiments of the invention provide epithelial cell adhesion molecule (EpCAM) binding polypeptides, as well as conjugates and CSANs comprising such polypeptides. Additionally, certain embodiments of the invention also provide methods of using such polypeptides and compounds for molecular imaging and molecularly targeted therapies.